Private Wellness Club Continuum Unlocks Final Membership Tier at West Village Flagship 
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on...
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive...
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform PDS Biotech to host conference call...
PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
D-PLEX100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of...
Tonix Pharmaceuticals to Present at Biotech Showcase 2023
CHATHAM, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment...
Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering
Psychedelic Drug DMT - Stroke Treatment Trial VANCOUVER, British Columbia, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company”...
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference
Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will...
Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours
Harren Jhoti OBE, PhD, FRS, FMedSci Astex Pharmaceuticals (UK), co-founder and CEO, Harren Jhoti OBE, PhD, FRS, FMedSci next to...
Biora Therapeutics Announces Reverse Stock Split
SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Carlsbad, CA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute...
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentationSTAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq:...
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous...
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage...
Connect Biopharma Provides Business and Clinical Development Program Update
Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3...
BiondVax CEO Issues Letter to Shareholders
JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing,...
Avicanna Announces Organizational Change in Avicanna LATAM S.A.S
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH...
BBS-Bioactive Bone Substitutes Plc – Insider information: BBS updates estimate of the CE marking approval schedule of ARTEBONE® Paste
BBS-Bioactive Bone Substitutes, Company announcement, Insider information, 30 December 2022 at 2:00 p.m. BBS updates estimate of the CE marking approval schedule of ARTEBONE®...